Characterization of LncRNA SNHG22 as a protector of NKIRAS2 through miR-4492 binding in osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Long noncoding RNAs (LncRNAs) are implicated in osteosarcoma (OS) tumorigenesis.
• Small nucleolar RNA host genes (SNHGs), a LncRNA subgroup, are potentially significant in OS.
• Small nucleolar RNA host gene 22 (SNHG22) has shown potential in inhibiting OS growth and metastasis.

Purpose of the Study:

• To elucidate the underlying mechanism of SNHG22 in regulating osteosarcoma (OS) progression.
• To validate the role of SNHG22 in inhibiting OS growth and metastasis.
• To investigate the interaction between SNHG22, miR-4492, and NKIRAS2 in OS.

Main Methods:

• Quantitative real-time PCR to assess SNHG22 expression.
• In vivo and in vitro experiments to evaluate the effect of SNHG22 overexpression on OS progression.
• RNA pull-down and RNA immunoprecipitation assays to validate SNHG22 and miR-4492 interaction.
• Dual-luciferase reporter assays to confirm the competing endogenous RNA (ceRNA) mechanism.

Main Results:

• SNHG22 expression was found to be downregulated in OS tissues.
• Overexpression of SNHG22 significantly inhibited OS progression both in vivo and in vitro.
• SNHG22 overexpression suppressed human umbilical vein endothelial cell (HUVEC) migration and proliferation and prevented epithelial-to-mesenchymal transition (EMT) in OS.
• SNHG22 directly interacts with miR-4492 and upregulates NKIRAS2 via ceRNA activity.

Conclusions:

• SNHG22 plays a crucial role in inhibiting osteosarcoma (OS) progression.
• The mechanism involves SNHG22 acting as a competing endogenous RNA (ceRNA) for miR-4492, thereby upregulating NKIRAS2.
• SNHG22 represents a potential novel therapeutic target for osteosarcoma (OS).